Inhibition of Cat S is predicted to suppress antigen presentation via MHC class II, T-cell, and B-cell activation and antibody production by B cells; thus, Cat S is an attractive therapeutic target for SLE [18,25], but the potential effect on SLE-PAH is not clear. Here, CAT is linked to systemic lupus erythematosus.